Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Intuitive Surgical

A turbulent market can be tough for investors, but great companies remain ripe for the picking. Intuitive Surgical has seen a slowdown in procedure volumes recently, but it's for short-term reasons.

Have $2,000? 2 Exceptional Stocks to Buy In a Bear Market

Novartis

Despite an unfavorable macro environment in 2022, some stocks did manage to churn out respectable gains last year. Novartis and Vertex Pharmaceuticals were two of last year's biggest winners within the large-cap space.

What Bear Market? These 2 Winning Stocks Are Still Worth Buying.

Pinterest

Growth stocks are facing headwinds at the moment, but not all such stocks are falling. Vertex continues to enrich investors in a turbulent market, and it's not hard to understand why.

2 Top Stocks to Buy With $1,000 Right Now

Etsy

Investing consistently in both up and down markets can help you toward your long-term financial goals. Vertex boasts a profitable portfolio, and it could see another approval around the corner.

2 No-Brainer Stocks to Buy Before the Next Bull Market

Innovative Industrial Properties

Even if another bear market happens, these businesses have what it takes to thrive and survive over the long haul. Vertex Pharmaceuticals serves a growing addressable market with its portfolio of profitable cystic fibrosis drugs.

2 No-Brainer Growth Stocks to Buy and Hold for Years

AbbVie

Vertex and AbbVie both beat the bear market last year. Both these top companies have reached an important moment in their stories -- and more growth may be on the horizon.

Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie

Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.

Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug

Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) is positioned to make a new run at the 52-week high of $325.19 as the stock is confirming a cup base pattern. The biotechnology company's stock is up 7.3% in the last month and just announced some news that could send the stock much higher.

Bullish News May Push Vertex Pharmaceuticals Above 52-Week High

CRISPR Therapeutics

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics' gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex's hypoimmune cell therapies for type 1 diabetes (T1D).

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

Amazon

Mastercard

NVIDIA

Two stocks that could make investors a lot of money are poised to benefit from the AI boom. One of the stocks is arguably more aligned with the U.S. economy's future than any other stock on the market.

Want $1 Million in Retirement? Buy and Hold These 5 Stocks

DexCom

The Nasdaq Composite index has been down for over a year now, but some of its components are soaring. Vertex Pharmaceuticals is the only drugmaker selling lifesaving treatments for patients who inherit a lethal disorder.

Nasdaq Bear Market: 2 Growth Stocks to Buy That Keep Bucking the Trend

Amphastar Pharma

Catalyst Pharmaceuticals

Enliven Therapeutics Inc

Horizon Pharma

The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.

The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks

Vertex Pharmaceuticals' business is insulated from the effects of economic cycles. The biotech's history of innovation continues, and it's aiming to diversify its lineup.

This Is My Highest-Conviction Stock to Own in 2023 and Beyond

Vertex Q4 2022 revenue was up 11% y/y. Trikafta continues to dominate the cystic fibrosis space.

Vertex Pharmaceuticals For Strong CF Franchise Growth Plus Exciting Pipeline

NextEra Energy

AT&T

A few recession-forecasting tools suggest a growing likelihood of a U.S. recession. The following three stocks are ideally positioned to excel no matter what the U.S. economy throws their way.

3 Surefire Stocks That Can Thrive During a Recession

Brookfield Renewable Partners

Dollar General

Brookfield Renewable is poised to profit from an unstoppable trend. Dollar General should thrive even if the banking sector's troubles worsen.

Worried About the Banking Turmoil? These 3 Stocks Shouldn't Skip a Beat

GlaxoSmithKline

vTv Therapeutics

When it comes to finding good pharma stocks to buy, I try to focus on companies that are developing drugs that can help huge numbers of people. After all, high profits are the ultimate key catalyst for stocks, and it's much easier for companies to generate gigantic profits if there is a huge demand for the products they are developing.

3 Pharma Stocks That Could Benefit from Global Healthcare Trends

Vertex is a Cystic Fibrosis powerhouse that earned revenues of $8.9bn in 2022 and was highly profitable. The company has been criticized in the past for a failure to diversify into other fields. Not any more.

Vertex: On The Verge Of Becoming A Very Serious Proposition For Buyers

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine (NEJM) of results from preclinical studies and a Phase 2 study evaluating the efficacy and safety of inaxaplin (VX-147) on top of standard-of-care in people with focal segmental glomerulosclerosis (FSGS) and two APOL1 variants, a severe, rapidly progressive form of chronic kidney disease also known as APOL1-mediated kidney disease (AMKD).

Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)

Moderna

With three pipeline candidates in phase 3 clinical trials, Moderna is set to enter a new phase of growth. CRISPR Therapeutics may soon reach a big milestone -- the launch of its first approved product.

2 Top Biotech Stocks to Buy for the Long Haul

Alphabet

The rise of AI and quantum computing could land Alphabet a spot in the Dow. Amazon's e-commerce and cloud-hosting growth could make it an irresistible choice for inclusion in the blue-chip index.

Prediction: These 3 Stocks Will Be in the Dow by 2030

Vertex Pharmaceuticals (VRTX) receives FDA clearance to begin clinical development of VX-264, which has the potential to treat type I diabetes.

Vertex (VRTX) to Begin Clinical Study on Type I Diabetes Drug

Vertex's next launch could open the door to a multibillion-dollar opportunity. The company also has other treatment candidates, not to mention its flagship lineup.

This HealthCare Company Is Gearing Up for Its Next Launch: Here Is Why The Stock Is a Buy

Beam Therapeutics

Editas Medicine

Intellia Therapeutics

Regeneron Pharmaceuticals

Verve Therapeutics

These CRISPR stocks could be big winners for patient investors.

Investing in Top CRISPR Companies

Healthcare businesses tend to remain resilient even amid economic turmoil. Vertex could soon have another blockbuster on its hands, and its existing portfolio remains strong.

News for Vertex Pharmaceuticals Stock (VRTX)